HK1172346A1 - Peptide vaccines for cancers expressing tumor-associated antigens - Google Patents

Peptide vaccines for cancers expressing tumor-associated antigens

Info

Publication number
HK1172346A1
HK1172346A1 HK12112989A HK12112989A HK1172346A1 HK 1172346 A1 HK1172346 A1 HK 1172346A1 HK 12112989 A HK12112989 A HK 12112989A HK 12112989 A HK12112989 A HK 12112989A HK 1172346 A1 HK1172346 A1 HK 1172346A1
Authority
HK
Hong Kong
Prior art keywords
associated antigens
expressing tumor
peptide vaccines
cancers expressing
cancers
Prior art date
Application number
HK12112989A
Other languages
English (en)
Chinese (zh)
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of HK1172346A1 publication Critical patent/HK1172346A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464434—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
HK12112989A 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens HK1172346A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21

Publications (1)

Publication Number Publication Date
HK1172346A1 true HK1172346A1 (en) 2013-04-19

Family

ID=39709837

Family Applications (7)

Application Number Title Priority Date Filing Date
HK12112989A HK1172346A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112899.3A HK1172043A1 (en) 2007-02-21 2010-03-10 Epha4 derived peptide vaccines epha4
HK10102517.8A HK1134507A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112988.5A HK1172345A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing hig2 tumor-associated antigens hig2
HK12112898.4A HK1172042A1 (zh) 2007-02-21 2010-03-10 用於表達腫瘤相關抗原的癌症的肽疫苗
HK12112897.5A HK1172041A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112987.6A HK1172344A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens

Family Applications After (6)

Application Number Title Priority Date Filing Date
HK12112899.3A HK1172043A1 (en) 2007-02-21 2010-03-10 Epha4 derived peptide vaccines epha4
HK10102517.8A HK1134507A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112988.5A HK1172345A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing hig2 tumor-associated antigens hig2
HK12112898.4A HK1172042A1 (zh) 2007-02-21 2010-03-10 用於表達腫瘤相關抗原的癌症的肽疫苗
HK12112897.5A HK1172041A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens
HK12112987.6A HK1172344A1 (en) 2007-02-21 2010-03-10 Peptide vaccines for cancers expressing tumor-associated antigens

Country Status (28)

Country Link
EP (20) EP2476695A3 (xx)
JP (6) JP5239103B2 (xx)
KR (8) KR20150116463A (xx)
CN (4) CN104292299B (xx)
AR (1) AR068302A1 (xx)
AU (1) AU2008218463B2 (xx)
BR (1) BRPI0808421B1 (xx)
CA (3) CA2919248A1 (xx)
CO (1) CO6190536A2 (xx)
CY (2) CY1114590T1 (xx)
DK (3) DK2476694T3 (xx)
ES (6) ES2532708T3 (xx)
HK (7) HK1172346A1 (xx)
HR (3) HRP20131044T1 (xx)
IL (10) IL200478A (xx)
MX (4) MX337456B (xx)
MY (2) MY173379A (xx)
NZ (4) NZ602119A (xx)
PH (1) PH12014501642B1 (xx)
PL (3) PL2465864T3 (xx)
PT (2) PT2465864E (xx)
RU (1) RU2464275C2 (xx)
SG (3) SG10201506589WA (xx)
SI (3) SI2121731T1 (xx)
TW (5) TWI615403B (xx)
UA (1) UA100372C2 (xx)
WO (1) WO2008102557A1 (xx)
ZA (1) ZA200905881B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660677A2 (en) 2003-08-20 2006-05-31 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
CN104356225B (zh) 2007-08-20 2018-02-13 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
RU2011103199A (ru) 2008-06-30 2012-08-10 Онкотерапи Сайенс, Инк. (Jp) Антитела против cdh3, меченные радиоизотопной меткой, и их применение
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
MX2011004176A (es) * 2008-10-22 2011-09-21 Oncotherapy Science Inc Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
BRPI0923402A2 (pt) * 2008-12-24 2015-08-04 Oncotherapy Science Inc Peptídeos c10rf59 e vacinas incluindo os mesmos.
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
TW201627003A (zh) * 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
MX344586B (es) * 2010-12-02 2016-12-20 Oncotherapy Science Inc Peptidos tomm34 y vacunas que los incluyen.
US9452182B2 (en) * 2011-12-14 2016-09-27 Board Of Regents, The University Of Texas System Collateral gene inactivation biomarkers and targets for cancer therapy
SG11201405578TA (en) * 2012-03-09 2014-11-27 Oncotherapy Science Inc Pharmaceutical composition containing peptide
EP2872531A4 (en) * 2012-07-10 2016-04-06 Oncotherapy Science Inc LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
EP2872530A4 (en) * 2012-07-10 2016-04-06 Oncotherapy Science Inc KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
WO2014034754A1 (ja) * 2012-08-31 2014-03-06 塩野義製薬株式会社 Psf1由来ペプチド
MX362912B (es) 2012-09-11 2019-02-22 Oncotherapy Science Inc Péptidos ube2t y vacunas que incluyen los mismos.
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
WO2015005479A1 (ja) * 2013-07-12 2015-01-15 大日本住友製薬株式会社 腫瘍抗原ペプチド
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
WO2016001810A1 (en) 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
KR20170030649A (ko) * 2014-08-04 2017-03-17 온코세라피 사이언스 가부시키가이샤 Urlc10-유래 펩티드 및 이를 포함하는 백신
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
WO2018090257A1 (zh) * 2016-11-16 2018-05-24 深圳华大基因研究院 多肽及其应用
SI3573600T1 (sl) 2017-01-25 2022-07-29 Ose Immunotherapeutics Postopek za proizvodnjo obstojne emulzije za dostavo peptida
WO2018183447A1 (en) * 2017-03-28 2018-10-04 Zhenglun Zhu Methods of treating neoplastic diseases
US11969463B2 (en) * 2017-08-10 2024-04-30 Good T Cells, Inc. Method for activating T cells for cancer treatment
US20210038703A1 (en) * 2018-02-15 2021-02-11 National University Corporation Asahikawa Medical University Cancer Antigen Peptide
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP1464706A3 (en) * 1994-04-15 2004-11-03 Amgen Inc., HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
DE69635895D1 (de) 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
AU6795898A (en) * 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1627886A1 (en) * 1997-10-07 2006-02-22 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use of them
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AU1220001A (en) * 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
WO2002008765A2 (en) 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
AU2002311787A1 (en) * 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
EP1463928A2 (en) * 2001-04-18 2004-10-06 Protein Design Labs Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CN1653080A (zh) * 2002-03-07 2005-08-10 路德维格癌症研究院 淋巴管和血管的内皮细胞基因
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2507924A1 (en) * 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20040235071A1 (en) * 2002-12-20 2004-11-25 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 or 13249
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1660677A2 (en) * 2003-08-20 2006-05-31 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
US20070253954A1 (en) * 2004-02-27 2007-11-01 Oncotherapy Science, Inc. Epha4 As Therapeutic Target Of Prc And Pdaca
WO2005097189A1 (ja) * 2004-04-09 2005-10-20 Genecare Research Institute Co., Ltd. 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2008509654A (ja) * 2004-06-01 2008-04-03 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
MX2007010349A (es) * 2005-02-24 2008-04-09 Cemines Inc Composiciones y metodos para clasificar muestras biologicas.
DK2325305T3 (en) * 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
AU2006277295B2 (en) * 2005-08-09 2011-08-11 Oncotherapy Science, Inc. Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same
EP1930427B1 (en) * 2005-08-09 2012-04-11 Kurume University Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
WO2007064743A2 (en) * 2005-11-30 2007-06-07 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP5290148B2 (ja) * 2006-04-10 2013-09-18 ジェネンテック， インコーポレイテッド Ｄｉｓｈｅｖｅｌｅｄ（Ｄｖｌ）ＰＤＺ修飾因子
ATE509096T1 (de) * 2006-06-16 2011-05-15 Onco Therapy Science Inc Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
US20090081659A1 (en) * 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
CN104356225B (zh) * 2007-08-20 2018-02-13 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
CA2775978A1 (en) * 2009-09-29 2011-04-07 Protagen Ag Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof

Also Published As

Publication number Publication date
PL2121731T3 (pl) 2014-01-31
SG10201909675QA (en) 2019-11-28
JP5239104B2 (ja) 2013-07-17
CA2678755C (en) 2016-04-26
KR20150018895A (ko) 2015-02-24
EP2583976A3 (en) 2013-10-23
EP2121731B1 (en) 2013-08-14
AU2008218463A2 (en) 2009-11-26
EP2465866A2 (en) 2012-06-20
CY1115841T1 (el) 2017-01-25
IL219040A0 (en) 2012-05-31
IL219042A0 (en) 2012-05-31
IL219044A0 (en) 2012-05-31
KR101511140B1 (ko) 2015-04-10
CO6190536A2 (es) 2010-08-19
EP2594581A2 (en) 2013-05-22
TW201433574A (zh) 2014-09-01
SI2465864T1 (sl) 2014-12-31
IL219048A (en) 2015-07-30
CN102863514B (zh) 2014-12-10
EP2570428A2 (en) 2013-03-20
EP2476692A2 (en) 2012-07-18
SI2476694T1 (sl) 2015-02-27
CA2919248A1 (en) 2008-08-28
EP2594582A2 (en) 2013-05-22
SI2121731T1 (sl) 2013-10-30
CA2992074C (en) 2021-01-05
WO2008102557A1 (en) 2008-08-28
NZ591704A (en) 2012-09-28
EP2573109A2 (en) 2013-03-27
HK1172345A1 (en) 2013-04-19
TW201623325A (zh) 2016-07-01
TW200844111A (en) 2008-11-16
JP2016094459A (ja) 2016-05-26
EP2567971A3 (en) 2013-06-26
CA2992074A1 (en) 2008-08-28
EP2476692A3 (en) 2012-12-19
AR068302A1 (es) 2009-11-11
KR101543623B1 (ko) 2015-08-11
ES2532708T3 (es) 2015-03-31
PT2465864E (pt) 2015-01-14
IL219045A0 (en) 2012-05-31
ES2527397T3 (es) 2015-01-23
MX2009009022A (es) 2010-03-03
EP2476693A2 (en) 2012-07-18
ZA200905881B (en) 2010-05-26
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
EP2574623A3 (en) 2013-07-17
ES2530777T3 (es) 2015-03-05
TWI596109B (zh) 2017-08-21
NZ579768A (en) 2012-03-30
BRPI0808421A2 (pt) 2017-08-29
EP2573109A3 (en) 2013-06-19
EP2476693B1 (en) 2014-12-24
AU2008218463B2 (en) 2013-01-17
IL219041A (en) 2014-12-31
EP2465865A2 (en) 2012-06-20
EP2573110A2 (en) 2013-03-27
KR101644871B1 (ko) 2016-08-02
KR20090121349A (ko) 2009-11-25
TWI438207B (zh) 2014-05-21
JP2013116895A (ja) 2013-06-13
KR20150116463A (ko) 2015-10-15
MX359680B (es) 2018-09-28
CN103351423B (zh) 2016-09-28
EP2476695A3 (en) 2012-12-12
ES2540893T3 (es) 2015-07-14
EP2567971A2 (en) 2013-03-13
KR20130023407A (ko) 2013-03-07
RU2009135020A (ru) 2011-03-27
IL219043A (en) 2014-12-31
TWI610939B (zh) 2018-01-11
KR101511134B1 (ko) 2015-04-28
EP2465864A3 (en) 2012-10-03
EP2465867B1 (en) 2015-04-01
EP2121731A4 (en) 2010-04-21
CN103351423A (zh) 2013-10-16
EP2465867A3 (en) 2012-10-10
EP2476694B1 (en) 2014-11-19
CA2678755A1 (en) 2008-08-28
UA100372C2 (ru) 2012-12-25
PL2465864T3 (pl) 2015-03-31
EP2570429A2 (en) 2013-03-20
IL219042A (en) 2016-03-31
AU2008218463A1 (en) 2008-08-28
JP5608953B2 (ja) 2014-10-22
ES2435194T3 (es) 2013-12-16
NZ602122A (en) 2014-03-28
IL219048A0 (en) 2012-05-31
HK1172041A1 (en) 2013-04-12
TWI615403B (zh) 2018-02-21
IL200478A0 (en) 2010-04-29
RU2464275C2 (ru) 2012-10-20
IL219041A0 (en) 2012-05-31
PH12014501642A1 (en) 2015-12-02
PL2476694T3 (pl) 2015-04-30
IL219046A (en) 2015-02-26
DK2121731T3 (da) 2013-10-21
EP2570430A3 (en) 2013-07-10
TW201538522A (zh) 2015-10-16
EP2465866A3 (en) 2012-10-10
HK1134507A1 (en) 2010-04-30
SG179402A1 (en) 2012-04-27
HK1172344A1 (en) 2013-04-19
JP2013091645A (ja) 2013-05-16
EP2476693A3 (en) 2012-10-03
DK2476694T3 (en) 2014-12-08
EP2574623A2 (en) 2013-04-03
TW201422637A (zh) 2014-06-16
IL219044A (en) 2014-12-31
EP2476692B1 (en) 2015-04-15
KR101540000B1 (ko) 2015-07-29
KR20140121489A (ko) 2014-10-15
HRP20141233T1 (hr) 2015-02-27
EP2465865B1 (en) 2016-11-02
EP2594582A3 (en) 2013-08-14
EP2476695A2 (en) 2012-07-18
IL219043A0 (en) 2012-05-31
EP2121731A1 (en) 2009-11-25
EP2465864B1 (en) 2014-10-08
TWI494319B (zh) 2015-08-01
SG10201506589WA (en) 2015-09-29
JP2014210804A (ja) 2014-11-13
KR20150064236A (ko) 2015-06-10
MY173379A (en) 2020-01-21
EP2476694A2 (en) 2012-07-18
HK1172043A1 (en) 2013-04-12
EP2570429A3 (en) 2013-08-28
EP2465865A3 (en) 2013-07-24
CY1114590T1 (el) 2016-10-05
IL219040A (en) 2014-12-31
EP2476694A3 (en) 2013-04-24
KR20160045939A (ko) 2016-04-27
JP5239103B2 (ja) 2013-07-17
CN101663315B (zh) 2014-10-15
EP2594581A3 (en) 2013-08-14
HRP20150108T1 (hr) 2015-05-08
EP2465864A2 (en) 2012-06-20
EP2570430A2 (en) 2013-03-20
JP2010209060A (ja) 2010-09-24
CN104292299B (zh) 2017-09-29
CN104292299A (zh) 2015-01-21
EP2565203A1 (en) 2013-03-06
EP2583976A2 (en) 2013-04-24
BRPI0808421B1 (pt) 2021-10-05
MX337456B (es) 2016-03-03
JP5874158B2 (ja) 2016-03-02
JP2010519176A (ja) 2010-06-03
PT2121731E (pt) 2013-10-24
KR20140130507A (ko) 2014-11-10
IL219047A0 (en) 2012-05-31
CN102863514A (zh) 2013-01-09
DK2465864T3 (en) 2014-11-24
ES2541863T3 (es) 2015-07-27
MY155029A (en) 2015-08-28
NZ602119A (en) 2014-03-28
CN101663315A (zh) 2010-03-03
EP2573110A3 (en) 2013-09-04
HK1172042A1 (zh) 2013-04-12
IL200478A (en) 2015-11-30
PH12014501642B1 (en) 2015-12-02
EP2465867A2 (en) 2012-06-20
JP5614761B2 (ja) 2014-10-29
KR101644877B1 (ko) 2016-08-03
MX337417B (es) 2016-03-03
HRP20131044T1 (hr) 2013-12-06

Similar Documents

Publication Publication Date Title
IL219047A0 (en) Peptide vaccines for cancers expressing tumor-associated antigens
IL228948A0 (en) Antibody against cancer antigen-helping peptide
HK1171024A1 (en) Peptide vaccines for cancers expressing mphosph1 polypeptides mphosph1
EP2006377A4 (en) NEW TUMORANT PEPTIDES
IL200615A0 (en) Monoclonal human tumor-specific antibody
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
EP2106442A4 (en) ANTIBODIES MODIFYING CANCER DISEASE
HK1142813A1 (en) Survivin peptides as cancer vaccines
EP2104732A4 (en) ANTIBODIES FOR THE MODIFICATION OF CANCER DISEASES
EP2106441A4 (en) ANTIBODIES FOR THE MODIFICATION OF CANCER DISEASES
EP2455102A4 (en) CANCER THERAPEUTIC AGENT COMPRISING AN ANTIBODY AGAINST CANCER SPECIFIC MEMBRANE ANTIGEN
GB0720156D0 (en) Breast cancer associated antigen
IL197737A0 (en) Antigen specific multi epitope vaccines
GB0716224D0 (en) Peptides for vaccine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230221